NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT01512589 2026-04-15
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02864992 2026-04-13
VISION
EMD Serono
Phase 2 Active not recruiting
NCT04644770 2026-04-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06939452 2026-04-07
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
The First Affiliated Hospital of Zhengzhou University
Phase 2 Active not recruiting
NCT06504615 2026-04-03
METAGIO
Bristol-Myers Squibb
Active not recruiting
NCT05063565 2026-03-27
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT05014776 2026-02-24
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT06564844 2026-01-27
TROPION-Lung12
AstraZeneca
Phase 3 Active not recruiting
NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting